S-1: Palisade Bio Launches $115M Offering Amidst Nasdaq Delisting Threat

Palisade Bio, a clinical-stage biopharmaceutical company, is offering up to 147 million shares and pre-funded warrants to raise approximately $92.4 million for advancing its lead IBD candidate, PALI-2108, despite ongoing Nasdaq listing concerns and going concern doubt.

Summary

• Palisade Bio is offering 147,058,823 shares of common stock and/or pre-funded warrants, with an underwriters' over-allotment option for an additional 22,058,823 shares.
• The assumed public offering price is $0.68 per share, based on the closing price on September 24, 2025.
• The company expects to raise approximately $92.4 million in net proceeds, or $106.4 million if the over-allotment option is fully exercised.
• Proceeds are intended to fund PALI-2108's preclinical and clinical development, general research and development activities, and working capital needs.
• PALI-2108, a prodrug PDE4 inhibitor, is being developed for Inflammatory Bowel Disease (IBD), including Fibrostenotic Crohn's Disease (FSCD) and Ulcerative Colitis (UC).
• Positive Phase 1 clinical study results for PALI-2108 were announced for healthy volunteers (SAD, MAD, FE cohorts) and UC patients, with all 5 UC patients responding to treatment.
• The company plans to initiate a Phase 1b cohort in FSCD and subsequent Phase 2 clinical programs for FSCD and moderate to severe UC.
• Palisade Bio is currently not in compliance with Nasdaq's minimum bid price requirement ($1.00) and faces a compliance deadline of October 27, 2025.
• The company does not currently satisfy the $5 million Stockholders Equity Requirement to be eligible for an additional compliance period, increasing delisting risk.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• A July 2025 Warrant Inducement Transaction generated approximately $3.9 million in gross cash proceeds.
• The company intends to seek stockholder approval for a reverse stock split at its annual meeting on October 17, 2025, to address the Nasdaq bid price deficiency.

Sentiment

Score: 4

Explanation: While positive Phase 1 clinical results for PALI-2108 offer a glimmer of hope for future development, the company's severe financial distress, including substantial doubt about its ability to continue as a going concern and the imminent threat of Nasdaq delisting, significantly overshadows these positives. The current capital raise, though critical, comes with substantial dilution for existing shareholders and highlights the precarious financial position.

Positives

• Positive results from the Phase 1 clinical study of PALI-2108 in healthy volunteers (SAD, MAD, and FE cohorts) were announced on May 27, 2025.
• Positive results from the UC cohort portion of the PALI-2108 study were announced on August 7, 2025, and September 17, 2025, with all 5 patients responding to treatment.
• PALI-2108 demonstrated rapid and consistent clinical activity in UC patients, showing promising signals of clinical improvement.
• Received a No Objection Letter from Health Canada on September 5, 2025, to conduct a Phase 1b cohort in FSCD.
• The China National Intellectual Property Administration issued a Notice of Allowance for the PALI-2108 patent in China in July 2025.
• The July 2025 Warrant Inducement Transaction generated approximately $3.9 million in gross cash proceeds, providing some capital infusion.

Negatives

• The company has received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement, with a compliance period ending October 27, 2025.
• Palisade Bio does not currently satisfy the $5 million Stockholders Equity Requirement, which is necessary to be eligible for an additional Nasdaq compliance period, increasing the risk of delisting.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The company has a history of net operating losses and expects to continue incurring them, with no revenues from product sales to date.
• Current cash resources are insufficient to fund anticipated operations through the completion of PALI-2108's planned future clinical studies.
• The offering will result in immediate and substantial dilution for existing stockholders, with up to 1,612.6% (or 1,854.5% with over-allotment) of current outstanding shares being offered.
• A material weakness in internal controls over financial reporting has been identified, related to the financial closing and reporting process.
• There is no established public trading market for the pre-funded warrants being offered, limiting their liquidity.

Risks

• Sales of a substantial number of common stock shares in the public market could cause the share price to fall.
• Management will have broad discretion in the use of the net proceeds from this offering, which may not align with all stockholders' approval.
• The market price of common stock has been, and will likely continue to be, volatile, potentially leading to loss of investment.
• Existing stockholders could experience substantial dilution of their ownership interest due to the issuance of shares and/or pre-funded warrants.
• The business depends on the successful clinical development, regulatory approval, and commercialization of therapeutic compounds, including PALI-2108.
• There are substantial risks in drug development, and PALI-2108 may not be successfully developed.
• Dependence on the license agreement with Giiant Pharma Inc. for PALI-2108 patents; termination or non-compliance could materially harm the business.
• The U.S. FDA or applicable foreign regulatory authorities may not accept data from Canadian clinical trials.
• Difficulty enrolling patients in clinical trials could delay or prevent proceeding with product candidates.
• Operations and development of PALI-2108 will require substantially more capital than currently available, with no guarantee of securing additional funding.
• PALI-2108 may cause undesirable side effects or have other unexpected properties, delaying regulatory approval or limiting commercial profile.
• There is no assurance that product candidates will obtain regulatory approval.
• If clinical studies of PALI-2108 do not yield successful results, development may be discontinued.
• Clinical trials may take longer than estimated or may not be completed at all.
• Even if PALI-2108 is approved, future regulatory reviews or inspections could result in suspension, withdrawal, facility closure, or substantial fines.
• Successful commercialization depends on adequate reimbursement levels and pricing policies from government authorities and health insurers.
• The company faces potential product liability exposure, which could result in substantial costs and limit commercialization.
• Even if approved, a product candidate may fail to achieve broad physician and patient adoption necessary for commercial success.
• The company has a limited operating history and has never generated revenues from product sales.
• The business model assumes revenue from marketing or out-licensing, but PALI-2108 is in early stages of clinical development.
• The company may choose to discontinue development or commercialization of any product candidates at any time.
• Inability to successfully in-license, acquire, develop, and market additional product candidates could impair business growth.
• Changes in funding for the FDA and other government agencies could hinder their ability to perform normal business functions, impacting the company.
• Reliance on third-party Contract Research Organizations (CROs) and other third parties to conduct clinical trials; failure to meet requirements could impede progress.
• Dependence on two qualified suppliers for the active pharmaceutical ingredient (API) of PALI-2108; insufficient availability or supply issues could adversely impact business.
• Reliance on collaborations with third parties for successful development and commercialization.
• Reliance on third-party contractors to supply, manufacture, and distribute clinical drug supplies.
• Substantial doubt about the company's ability to continue as a going concern.
• History of net operating losses and expectation to continue incurring them, potentially never achieving profitability.
• Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements.
• Inability to obtain, maintain, or enforce global patent rights or other intellectual property rights of sufficient breadth.
• Failure to comply with intellectual property license agreements could lead to loss of critical license rights.
• Potential exposure to patent infringement claims, resulting in substantial costs and liabilities.
• Subject to claims that officers, directors, employees, or consultants have wrongfully used or disclosed trade secrets of former employers.
• Need to raise additional financing in the future, which may not be available on favorable terms or at all.
• Common stock price may be highly volatile.
• Common stock could be delisted from the Nasdaq Stock Market if compliance with listing standards is not maintained.
• Taking advantage of reduced disclosure and governance requirements as a smaller reporting company could make common stock less attractive to investors.
• No anticipation of paying dividends in the foreseeable future.
• If equity research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Future sales of substantial amounts of common stock could adversely affect the market price.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements.
• The Board has broad discretion to issue additional securities, which might dilute existing stockholders.
• Business could be adversely affected by health pandemics or epidemics.
• Global economic conditions may have an adverse effect on the business.
• Inadequate funding for the FDA, SEC, and other government agencies, including from government shutdowns, could hinder operations.
• Information systems or data, or those of third parties, being compromised could lead to adverse consequences.
• Business and operations would suffer in the event of system failures, cyber-attacks, or a deficiency in cybersecurity.

Future Outlook

The company plans to initiate an additional safety, tolerability, and PK/PD exploratory Phase 1b cohort for PALI-2108 in Fibrostenotic Crohn's Disease (FSCD), following the completion of longer-term chronic safety and toxicology studies. This will be succeeded by the initiation of Phase 2 clinical programs to evaluate PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe Ulcerative Colitis (UC). Additionally, the company intends to seek stockholder approval for a reverse stock split at its annual meeting on October 17, 2025, as a measure to regain compliance with Nasdaq's minimum bid price requirement.

Management Comments

• Our objective is to establish ourselves as a leader in the development of differentiated product candidates targeting the autoimmune, inflammatory, and fibrotic disease markets, which we believe will address a large, well-established need among patients living with autoimmune and inflammatory diseases.
• We believe PALI-2108 has the potential to provide a much needed first-in-class therapy for patients with Fibrostenotic Crohn's Disease.
• Based on our clinical research and development, we believe that PALI-2108 has the potential to address many of the areas of needed improvement in Inflammatory Bowel Disease treatments.

Industry Context

The biopharmaceutical industry is actively seeking innovative treatments for autoimmune, inflammatory, and fibrotic diseases, particularly Inflammatory Bowel Disease (IBD). The global market for Crohn's disease treatments was valued at $13.9 billion in 2022, projected to grow to $25.5 billion by 2032, while the ulcerative colitis market in the 8MM was $7.3 billion in 2021, expected to reach over $9.5 billion by 2031. There are significant unmet needs in IBD, including inadequate primary response to existing treatments, secondary loss of response, challenges in patient selection, safety concerns with long-term medication, and limited options for refractory or severe disease. Palisade Bio's PALI-2108, a locally bioactivated PDE4 inhibitor, aims to address these gaps by targeting both inflammatory and fibrotic components, especially in Fibrostenotic Crohn's Disease where no approved therapies specifically exist. The company's precision medicine approach, utilizing biomarker-based patient selection, aligns with broader industry trends towards personalized medicine to improve treatment outcomes.

Comparison to Industry Standards

• PALI-2108 is positioned as a potential first-in-class therapy for Fibrostenotic Crohn's Disease (FSCD), an area with limited existing treatment options, which are primarily invasive procedures like balloon dilation, strictureplasty, and bowel resection.
• PDE4 inhibitors are a clinically and commercially proven class of drugs with dual anti-inflammatory and anti-fibrotic properties, providing a known mechanism of action for PALI-2108.
• PALI-2108's innovative localized bioactivation mechanism is designed to prevent the systemic toxicity and known tolerability issues associated with other PDE4 inhibitors, potentially offering a better safety and tolerability profile compared to existing systemic PDE4 inhibitors.
• The company's strategy to develop a biomarker-based patient selection approach for PALI-2108 aims to improve clinical response rates, differentiating it from previous enzyme phosphodiesterase-4 (PDE4) inhibitors by identifying patients more likely to respond.

Management Changes

Corporate Governance

Legal Proceedings

• There is no action, suit, inquiry, notice of violation, proceeding, or investigation pending or threatened against or affecting the company or its subsidiaries that would adversely affect the legality, validity, or enforceability of any Transaction Documents or Public Securities, or result in a Material Adverse Effect.
• Neither the company nor any subsidiary, nor any current director or officer, is or has been the subject of any action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• There has not been, and there is not pending or contemplated, any investigation by the Commission involving the company or any current or former director or officer of the company.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the company or any subsidiary under the Exchange Act or the Securities Act.

Related Party Transactions

• On August 16, 2022, J.D. Finley, the Chief Executive Officer and Chief Financial Officer, invested $25,000 in the company's underwritten offering, receiving 133 units consisting of common stock and warrants.
• Armistice Capital LLC, a holder of greater than 5% of outstanding common stock, purchased shares and warrants in a registered offering and concurrent private placement in April 2023 for an aggregate of $2,999,930.11.
• Armistice Capital LLC also purchased Class A and Class B Units in a December 2024 underwritten public offering for an aggregate purchase price of $4,999,687.13.
• On June 17, 2024, the company issued 5,603 shares of common stock, valued at $26,222.04, to MDM Worldwide Solutions, Inc., a consultant, as partial payment for business advisory services.
• On September 4, 2024, the company issued 14,029 restricted shares of common stock, valued at $50,644.69, to a consultant as partial payment for financial advisory services.
• On October 1, 2024, the company issued 3,000 restricted shares of common stock, valued at $10,650, to a consultant as partial payment for services.
• On February 11, 2025, J.D. Finley received options to purchase 47,000 shares (valued at ~$47,400) and 40,000 restricted stock units (valued at ~$45,200).
• On February 11, 2025, Mitchell Jones, Chief Medical Officer, received options to purchase 29,000 shares (valued at ~$29,200) and 24,000 restricted stock units (valued at ~$27,120).
• On July 23, 2025, the company entered into a warrant inducement agreement with an accredited and institutional holder (July 2025 Warrant Holder) of existing warrants, which resulted in the exercise of 4,318,905 existing warrants and the issuance of 8,637,810 new replacement warrants.

Stakeholder Impact

• Shareholders will experience significant dilution from the current offering, potentially reducing the value of their existing holdings. They also face the risk of the company's common stock being delisted from Nasdaq, which could negatively impact liquidity and market perception.
• Employees, particularly key scientific and management personnel, are crucial for the company's future success, and their retention is dependent on the company's ability to secure funding and advance its programs. Equity compensation plans are a significant part of their incentives.
• Patients suffering from Inflammatory Bowel Disease (IBD), including Fibrostenotic Crohn's Disease (FSCD) and Ulcerative Colitis (UC), could potentially benefit from PALI-2108 if it successfully completes clinical development and gains regulatory approval, offering a new treatment option for unmet needs.
• Creditors face increased risk due to management's expressed substantial doubt about the company's ability to continue as a going concern, which may affect the company's ability to meet its financial obligations.
• Suppliers and partners, including Contract Research Organizations (CROs) and Active Pharmaceutical Ingredient (API) manufacturers, are critical for the company's operations. Disruptions in these relationships or supply chains could severely impact development timelines and costs.

Next Steps

• Advance PALI-2108 through preclinical and clinical development and into Investigational New Drug (IND) applications or their equivalent in foreign jurisdictions.
• Fund ongoing research and development activities.
• Address general working capital needs.
• Initiate an additional safety, tolerability, and PK/PD exploratory Phase 1b cohort for PALI-2108 in Fibrostenotic Crohn's Disease (FSCD).
• Complete longer-term chronic safety and toxicology studies for PALI-2108.
• Initiate Phase 2 clinical programs to assess PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe Ulcerative Colitis (UC).
• Seek stockholder approval at the annual meeting on October 17, 2025, to effect a reverse stock split to address Nasdaq listing compliance.
• Remediate the identified material weakness in internal controls over financial reporting.
• Maintain compliance with Nasdaq's continued listing standards to avoid delisting.

Key Dates

Recommendation

The company faces critical financial challenges, including substantial doubt about its ability to continue as a going concern and an imminent threat of delisting from Nasdaq due to both minimum bid price and stockholders' equity non-compliance. While PALI-2108 shows promising early clinical data, the company lacks sufficient capital for future development, and the current offering, though necessary, will cause significant dilution for existing shareholders. The high level of uncertainty, immediate financial risks, and the need for continuous capital raises outweigh the potential long-term upside of the drug candidate at this stage, making it a high-risk investment with a strong likelihood of further value erosion for current holders.

Keywords

Biopharmaceutical, Clinical-stage, IBD, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, PALI-2108, PDE4 inhibitor, Prodrug, Fibrosis, Autoimmune, Inflammatory, Nasdaq, SEC filing, S-1, Public Offering, Warrants, Capital Raise, Going Concern, Clinical Trials, Drug Development, Biotechnology, Delisting Risk, Dilution